Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| IRCT20160406027253N3 | Other Identifier | IRCT (Iranian Registary ofClinical Trials) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to Investigate the Effect of Injection of MSC-Derived Exosome on Patients with Erectile Dysfunction in overall healthy males, aged 18-70, with-out any severe active medical condition, with moderate to severe erectile dysfunction based on IIEF-5, and non-satisfactory response to other treatments (5PDEI). The main question it aims to answer is:
• Is MSC-derived exosome safe and effective in treating patients with ED by improving IIEF-5 score?
If there is a comparison group: Researchers will compare the intervention group (Exosome receiving group) with control group (placebo receiving group) to see if exosomes are safe and effective in treating male adult patients with moderate-sever ED.
Participants will receive six weekly injections of normal saline or exosome (based on group), and will undergo necessarily follow up, and examinations and observation.
Secondary outcomes are the folllowing:
EHS score length of erected penis lenght of flacid penis (pulled) peak systolic volume (via dupler sonography) end diastolic volume (via dupler sonography) any adverse effects of exosome
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention (Exosome) | Experimental | patients in this arm will be injected 5 ml of exosome in corpus cavernosa of each side (2.5 ml in each side at base of the penis). This will happen once a week, for 6 weeks. Inorder to prevent the injected substance from spreading systemically, a tourniquet will be placed at the base of the penis for 10 minute following injection. |
|
| Control | Placebo Comparator | Control group: these patients will recieve 5 ml of intracavernosal normal saline (2.5 ml in each side of penile base). This will happen once a week, for 6 weeks. Inorder to prevent the injected substance from spreading systemically, a tourniquet will be placed at the base of the penis for 10 minute following injection. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| exosomes derived from human umbilical cord mesenchymal stem cells | Biological | Intervention group: patients in this group will be injected 5 ml of exosome in corpus cavernosa of each side (2.5 ml in each side at base of the penis). This will happen once a week, for 6 weeks. Inorder to prevent the injected substance from spreading systemically, a tourniquet will be placed at the base of the penis for 10 minute following injection. |
| Measure | Description | Time Frame |
|---|---|---|
| IIEF-5 score | Erectile dysfunction of the patients during the study will be assessed by IIEF-5 questionnaire. It will done in a interview with the patients. | week 0, 7, 13, 25, 49 |
| Measure | Description | Time Frame |
|---|---|---|
| EHS score | Erectile Hardness Score It will be done in a interview with the patients. | week 0, 7, 13, 25, 49 |
| Peak Systolic Voulme | Peak systolic volum or arterial blood flow of the penis, which will be assessed by doppler sonography after papaverin injection |
Not provided
Inclusion Criteria:
Moderate or severe erectile dysfunction (according to IIEF-5) Non-satisfactory response to other treatments Generally Healthy males Not having severe past medical history
Exclusion Criteria:
Known allergy or history of hyperactivity to biological substances Peyronie's plaque Existing medical condition (severe or uncontrolled) Use of psychiatric medication Use of thyroid medication Hyopgonadism Hypergonadism Cancer History of prostatectomy Prostitis Autoimmune disease Recent trauma or surgery Ongoing systemic infection Skin lesion or infection at the site of injection
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shahid Labbafinejad Hospital | Tehran | Tehran Province | 1666663111 | Iran |
It is not yet known if there will be a plan to make this available.
Not provided
Not provided
Not provided
Not provided
Not provided
A single blinded randomized clinical trail with a placebo-controlled group, consisting 70 patients in total (35 patients in each arm)
Not provided
Not provided
Not provided
|
| Normal (0.9%) saline | Biological | Control group: these patients will recieve 5 ml of intracavernosal normal saline (2.5 ml in each side of penile base). This will happen once a week, for 6 weeks. Inorder to prevent the injected substance from spreading systemically, a tourniquet will be placed at the base of the penis for 10 minute following injection. |
|
| week 0, 7, 13 |
| End Diastolic Volume | end diastolic volume or venous blood flow of the penis which will be assessed by doppler sonography after papaverin injection | week 0, 7, 13 |
| Pulled length of penis | the pulled length of penis which will be assessed by clinician at each follow up session | week 0, 7, 13, 25, 49 |
| Erected length of Penis | erected length of penis which will be assessed at follow up sessions by clinician | week 0, 7, 13, 25, 49 |
| Side effects | any immeadiate, or late onset local side effects at injection site. these will be reported both by the patients and assessed by the clinician. | week 1, 2, 3, 4, 5, 6 |
| ID | Term |
|---|---|
| D007172 | Erectile Dysfunction |
| ID | Term |
|---|---|
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D012735 | Sexual Dysfunction, Physiological |
| D052801 | Male Urogenital Diseases |
| D020018 | Sexual Dysfunctions, Psychological |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017670 | Sodium Compounds |
Not provided
Not provided